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Abstract: Fumaric acid is an intermediate product of the citric acid cycle that is a source of intracellular energy in the 
form of adenosine triphosphate (ATP). It is generated by oxidation of adenylsuccinate by the enzyme succinate dehydro-
genase and is then converted to maleate by the enzyme fumarase. At present, fumaric acid esters (FAE) are licensed for 
the treatment of psoriasis. Several lines of evidence have demonstrated immunomodulatory effects for FAE. Clinical stud-
ies in psoriasis showed a reduction of peripheral CD4
+- and CD8
+-T-lymphocytes due to the ability of FAE to induce 
apoptosis. In vitro studies with the ester dimethyl fumarate (DMF) described an inhibitory effect on nuclear factor kappa 
B (NF-B)-dependent transcription of tumor necrosis factor-alpha (TNF-) induced genes in human endothelial cells. 
Animal studies using a model of central nervous system demyelination, MOG-induced experimental autoimmune en-
cephalomyelitis (EAE), revealed a reduction of microglia and macrophages in inflamed lesions. A phase II clinical study 
in relapsing-remitting multiple sclerosis (RRMS) patients with a modified fumaric acid ester, BG-12, showed as "proof of 
principle" a significant reduction in the number of gadolinium enhancing lesions after 24 weeks of treatment as compared 
to placebo. Further phase III studies have now started to explore the long-term efficacy of FAE. 
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INTRODUTION 
  Multiple sclerosis (MS) is the most common cause of 
neurological disability in young adults. The current treatment 
options for relapsing-remitting MS (RRMS) are only par-
tially effective and require a parenteral route of administra-
tion. Therefore, there is a need for new and well tolerated, 
preferably orally available therapeutics. 
  Fumaric acid esters (FAE) are a group of simple struc-
tured compounds that have been used in the treatment of 
psoriasis since 1959, originally proposed by the german 
chemist Schweckendiek [23]. He himself suffered from this 
disease and assumed that a disturbance in the citrate cycle 
might be the cause, since immune cells are so critically de-
pendent on energy supply. Over the next decades, a mixture 
of compounds consisting of dimethylfumarate (DMF) and 
three salts of ethylhydrogenfumarate (EHF) was developed 
to reduce (mainly gastrointestinal) side effects and was li-
censed in Germany in 1994 as oral therapy for serve psoria-
sis under the brand name Fumaderm
®. Over the past 15 
years, there have been many clinical trials that demonstrated 
the immunomodulatory efficacy and safety of oral FAE in 
this indication [3, 9, 15]. Due to its immunomodulatory po-
tential, FAE are also evaluated as a potential treatment for 
RRMS. Here we summarize the rationale for such investiga-
tions, the known mechanisms of action, and the results of 
early clinical trials. 
TREATMENT OF FAE IN PSORIASIS 
 Fumaderm
®, an enteric-coated tablet, has become the 
most prescribed systemic treatment for psoriasis in Germany  
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since 1994 [20]. A total of 13 studies confirmed that a pro-
portion of 50-70% of the patients showed an improvement of 
approximately 75% of the baseline “psoriasis area and ser-
vitiy index” (PASI) after 4 month of treatment [13, 15, 16, 
17]. Although there are some side effects like flushing, nau-
sea, vomiting and diarrhea in 30% of patients which typi-
cally limit the treatment period to 4-6 weeks, Fumaderm
®
showed an excellent antipsoriatic effect in clinical studies 
and appears to be fairly safe in comparison with other sys-
temic anti-psoriatic treatment options. Neither long-term 
toxicity, nor a higher risk for infections or malignancies have 
been observed [7]. Furthermore, there are no described inter-
actions with other drugs, except those known to have damag-
ing effects on the kidneys.  
PHARMACOLOGICAL PROPERTIES OF FAE 
  After oral intake, DMF, the main component of Fu-
maderm
®, is rapidly hydrolysed by esterases to its metabolite 
monomethyl fumarate (MMF). After complete absorption in 
the small intestine [29], it can interact with immune cells in 
the blood circulation [10]. MMF, the most bioactive metabo-
lite [18], is further metabolized in the citrate cycle to carbon 
dioxide and water and finally eliminated mainly though 
breathing while only small amounts of intact MMF are ex-
creted through urine or faeces. The half-life of DMF is about 
12 minutes and 36 hours for MMF. The highest concentra-
tion of MMF in human serum is measured 5 to 6 hours after 
oral intake. There is no evidence for a cytochrome P450 de-
pendent metabolism in the liver [16].  
MODE OF ACTION 
 Despite  numerous  in vitro and ex vivo studies, the 
mechanism of action of FAE is not fully understood. A con-
venient hypothesis is based on the idea that DMF interferes 
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thiols and thereby increasing the level of reduced glutathione 
[14]. These increased glutathione levels may finally lead to 
an inhibition of the translocation of NF-B into the nucleus. 
Altering the NF-B pathway results in a decreased expres-
sion of NF-B dependent genes that regulate the expression 
of a cascade of inflammatory cytokines, chemokines, and 
adhesion molecules [25]. This affects different types of cells 
in the immune system (Table 1) and their counterparts like 
the endothelium. However, at higher concentrations, DMF 
may induce apoptosis in all cell types. 
Effect of FAE on T-Cells 
  One of the first observations during the application of 
Fumaderm
® in psoriasis was the effect on T-cells. Initial 
studies revealed a decrease of T-cells in nearly all treated 
patients [2]. This finding was well in line with an immuno-
histochemical study that showed a reduction of CD4
+-cells 
by half [5] in the epidermal inflammatory infiltrate. Subse-
quent in vitro studies confirmed the capability of DMF to 
induce apoptosis in human T-cells [26]. Upon analysis of the 
cytokine production in more detail, de Jong et al. [6] re-
ported that MMF increased the production of the “TH2” cy-
tokines interleukin (IL)-4 and IL-5 in stimulated T-cells 
without having an effect on the “TH1” cytokine interferon 
gamma (IFN-), the IL-2 production, or the proliferation of 
T-cells. In another study, stimulated CD4
+CD45RO
+ mem-
ory T-cells again showed an increased secretion of IL-4 and 
IL-5 after treatment with MMF. Taken together, these find-
ings suggest that FAE shift the cytokine profile from a 
“TH1” to a “TH2” profile. This effect of FAE on the expres-
sion of cytokines may also apply to other cell types than T-
cells. 
Effects of FAE and Peripheral Blood Mononuclear Cells 
(PBMC) 
  In human PMBC stimulated either with IFN- or 
lipopolysaccharide (LPS) the expression of the chemokines 
CXCL8, CXCL9, and CXCL10 was dose dependently inhib-
ited by DMF [19]. Application of MMF led also to a higher 
expression of IL-4, IL-5, TNF-, IL-10 and IL-1RA which is 
well in line with the findings in T-cells [4]. In monocytes, 
FAE induced an upregulation of the production of superox-
ide anions [32]. 
Effects of FAE on B-Cells 
  Although there have not been any studies on direct FAE 
effects on B-cells, there is evidence that the downregulation 
of NF-B can inhibit the anti-apoptotic protein Bcl-2 which 
can in turn lead to apoptosis in B-cells [14]. It is thus tempt-
ing to speculate that FAE mediated inhibition of NF-B ac-
tivity may also affect B-cell functions and influence B-cell 
apoptosis. 
Effects of FAE in Keratinocytes 
  Keratinocytes are themselves expressing cytokines and 
chemokines and are part of the inflammatory response in 
psoriasis. Thus, their response to FAE was of great interest. 
Ockenfels et. al. [19] demonstrated that in keratinocytes co-
cultured with a T-cell line, DMF can increase the expression 
of IL-10 and inhibit IFN-, IL-6 and transforming growth 
factor (TGF)-. Another study with the keratinocyte cell line 
HaCat showed that DMF suppresses the expression of inter-
cellular adhesion molecule-1 (ICAM-1) and HLA-DR [24]. 
Recent studies revealed that DMF can also inhibit the ex-
pression of the chemokines CXCL1, CXCL8, CXCL9, 
Table 1.  Summary of the Effect of FAE in Different Cell Types 
Cell Type  Cytokine/Signaling Effect  MMF/DMF  Effect  References 
T-cells IL-10, IL-5,   MMF/DMF 
“TH1” “TH2” shift,  
HO-1
reduced CD4
+, CD8
+numbers 
[2, 5, 6, 26] 
PBMC 
CXCL8, 9, 10
TNF- , IL-10
 IL-1RA
IL-4, IL-5
DMF Superoxide  anions [4, 19, 32] 
B-cells NF-B n.d  Bcl-2, induce apoptosis  [14] 
Keratinocytes 
IFN,IL-10,
IL-6, TGF-,
CXCL8, 9, 10, 11
DMF HLA-DR,ICAM-1
[19, 24, 25]  
Dendritic cells  Il-12,   MMF/DMF 
induce apoptosis, prevent 
celldifferentitation 
[11, 31] 
Endothelial cells  prevent NF-B translocation   DMF 
TNF , ICAM-1, E-selectin
VCAM-1
[4, 27] 
Glia cells 
TNF-, IL-1,
 IL-6
DMF 
NQO-1,cellular Glutathion,
NO
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CXCL10 and CXCL11 in keratinocytes [25] which are to 
different degrees involved in chemoattraction of neutrophilic 
granulocytes, macrophages and T-cells.  
FAE and Dendritic Cells (DC) 
  Dendritic cells play a major role in regulating inflamma-
tory responses in autoimmune diseases like psoriasis and MS 
by expressing cytokines and co-stimulatory molecules. In 
monocyte derived DC, FAE prevented appropriate cell dif-
ferentiation [31]. In another study, MMF treated DC altered 
the lymphocyte response to a “TH1” profile after stimulation 
by lipopolysaccharide (LPS) [11]. 
FAE Effects on Endothelial Cells 
  In experiments with human umbilical vein endothelial 
cell cultures, Asadullah et al. and Vandermeeren et al.
showed that DMF inhibits the tumor necrosis factor (TNF)-
induced expression of ICAM-1, E-selectin, and the vascular 
cell adhesions molecule-1 (VCAM-1) [4, 27].  
Effects of FAE on Glial Cells 
  A potential detoxification effect was found when DMF 
was tested in astrocytes and microglia [30]. DMF decreased 
the LPS induced production of proinflammatory cytokines 
like TNF-, IL-1, IL-6, and nitric oxide. Moreover, DMF 
increased the expression of the NAD(P)H: quinine reductase 
(NQO-1) and the content of cellular glutathione. Both are 
involved in glial detoxification pathways which could poten-
tially add to a so far only poorly described neuroprotective 
effect of FAE. 
FAE IN EXPERIMENTAL AUTOIMMUNE EN-
CEPHALOMYELITIS (EAE) 
  Given the immunomodulatory properties of FAE, it was 
suggested that there may be also a beneficial effect in MS. 
Thus, Schilling et al. [21] investigated the effects of FAE in 
myelin oligodendrocyte glycoprotein (MOG) induced ex-
perimental autoimmune encephalomyelitis (MOG-EAE), an 
animal model mimicking several aspects of MS. Different 
dosages of FAE were administered by oral gavage starting 
from day 3 post immunization (p.i.). This study confirmed 
the positive effect of FAE. Histological analysis showed a 
significant reduction of microglia and macrophages, but not 
of T-cells at an early time point of the disease (day 26 p.i.) 
while cytokine analysis could not confirm a “TH1”-“Th2” 
shift. At later stages of the disease a significant preservation 
of myelin and axonal integrity was found. These effects cor-
related with the ability of FAE to induce Nrf2 dependent 
pathways which may mediate neuroprotective effects by 
increasing expression of NQO-1 and thus modulating the 
redox state in the inflamed central nervous system (CNS) 
[12]. 
FAE IN MULTIPLE SCLEROSIS 
 Schimrigk  et al. [22] completed a first exploratory, pro-
spective, open-label study of FAE in 10 patients with 
RRMS. The investigations included safety and tolerability, 
the amount and volume of gadolinium-enhancing (Gd+) le-
sions on MRI, the relapse rate, changes in the Expanded Dis-
ability Status Scale (EDSS), the ambulatory index (AI), the 
nine-hole peg test (9-HPT), and a detailed cytokine profile. 
Inclusion parameters were the presence of at least one active 
lesion on baseline MRI, at least one relapse in the year be-
fore the beginning of the study, and an EDSS score between 
2.0-6.0. There were four phases of the study: first a 6-week 
baseline monitoring phase, second an 18-week treatment 
phase, third a 4-week washout phase, and finally a second 
48-week treatment phase. The patients were given a titrated 
maximum of 720 mg/d Fumaderm
® in the first phase and 
360 mg/d in the second phase. FAE treatment led to a sig-
nificant reduction of Gd+ lesions already after the first 
treatment phase. This effect persisted during the second 
treatment phase even with only half of the dose. The EDSS, 
Table 2.  Clinical and MRI Data of a Phase II Study with BG-12 in RRMS
BG12  End Point 
MRI 
Placebo 
120 mg qd  120 mg tid  240 mg tid 
Mean number of new Gd+ lesions 
(Weeks 1224) 
4.5 3.3  3.1  1.4* 
Mean number of new or enlarging T2-
hyperintense lesions, 
% of patients (Week 24) 
4.2 3.8  4.1  2.2* 
Mean number of new T1-hypointense 
lesions,  % of patients (Week 24) 
1.7 1.3  1.5  0.8* 
Clinical Data 
(weeks 024) 
      
Annualized relapse rate  0.65  0.42  0.78  0.44 
Relapse free, % of patients  69  78  64  71 
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AI and the 9-HPT remained stable or showed a slight im-
provement as compared to baseline. Immunological investi-
gations revealed a small increase in the expression of IL-10 
and a higher apoptosis rate of CD4
+ lymphocytes. The main 
adverse events were gastrointestinal symptoms and flushing, 
all of which were reported as mild and reversible. These re-
sults supported the design of further clinical investigations. 
  In 2008 Kappos et al. [8] reported the results of a larger 
phase II study. This multicenter, double-blind, placebo-con-
trolled study included 257 patients in 10 countries and was 
designed to evaluate the safety, efficacy, and dose-ranging. 
The study used a second generation fumaric acid derivate 
(BG-12) that was developed by Fumapharm AG and Bio-
genIdec Inc. and contains DMF [1, 28] as enteric-coated 
microtablet to improve gastrointestinal tolerability. The 257 
patients were randomized in four groups to receive either 
placebo or BG-12 at 120, 360, 720 mg/d for 6 month, fol-
lowed by another 6 month of a dose-blinded safety extension 
study where the placebo group received the highest dose of 
720 mg/d. In this study, outcome parameters included the 
number and volume of Gd+ enhancing lesions, new or en-
larging T2, new T1 lesions, and annualized relapse rate (Ta-
ble 2). In comparison to the placebo group, the high-dose 
BG-12 group displayed a statistically significant reduction of 
69% in the mean number of Gd+ enhancing lesions as meas-
ured by monthly MRI between weeks 12 and 24. The 720 
mg/d group also showed a reduction in newly enlarging T2 
lesions of 48% and a reduction of 53% of T1 newly enlarg-
ing lesions as compared to the placebo group at week 24. 
Although the study was not designed to demonstrate an ef-
fect on the relapse rate, there was a trend toward a reduced 
annualized relapse rate by 32%. In the 120 mg/d and 360 
mg/d treated groups the results were not statistically signifi-
cant.  
  Adverse events included headache, mild infections, gas-
trointestinal symptoms, mild increase in liver enzymes and 
flushing which decreased during the second study phase and 
were all mild and reversible. In general, BG-12 appears to 
have a promising short-term efficacy and safety profile.  
  To determine the long-term safety and efficacy of BG-12, 
a phase III study program already started in Europe and 
North America. The program includes the DEFINE (deter-
mination of the efficacy and safety of oral fumarate in re-
lapsing-remitting MS) and CONFIRM (comparator and an 
oral fumarate in relapsing-remitting MS) studies. These trials 
are designed as international, multicenter, two-year random-
ized, double-blind, placebo-controlled, dose comparison 
studies. The CONFIRM study will also contain a glatimer 
acetate group to compare BG12 with an established immu-
nomodulatory therapy. These phase III studies will further 
elucidate the potential of BG12 in the treatment of RRMS. 
CONCLUSION 
  After the long experience in the treatment of psoriasis 
with more than 30000 patient years and several in vitro and 
animal studies, FAE seem a promising orally available op-
tion for the immunomodulatory treatment of patients with 
RRMS. Results from a phase II study support this potential. 
In particular, the new formulation BG12 displays an im-
proved tolerability and an excellent safety profile. Experi-
mental data suggest an immunomodulatory and an additional 
neuroprotective mechanism, making BG12 a promising tar-
get. The assumed immunomodulatory capacity will probably 
place BG12 in a similar range as the available injectable dis-
ease modifying drugs for treatment of RRMS in the early 
phase of the disease. Due to the excellent safety profile 
known from the use in psoriasis, BG12 may also prove to be 
a good candidate for combination therapies. The ongoing 
phase III clinical trials are designed to demonstrate the long-
term efficacy in a large cohort of patients with RRMS. The 
results are eagerly awaited by both patients and physicians to 
satisfy the great need for new safe and orally available 
treatment options. 
CONFLICT OF INTEREST 
  This article was written without financial support. MS, 
RL, and RG have received honoraria for consulting services 
and lectures from Baxter, BiogenIdec, Biotest, Bayer, 
MerckSerono, Novartis, Sanofi-Aventis, Talecris, and Teva. 
MS and RG have received research support from Bio-
genIdec, Bayer, MerckSerono, Sanofi-Aventis, and Teva. 
REFERENCES 
[1]  Anonymous. (2005) BG 12: BG 00012, BG 12/Oral Fumarate, 
FAG-201, second-generation fumarate derivative--Fumapharm/ 
Biogen Idec. Drugs R. D., 6, 229-230. 
[2]  Altmeyer, P., Hartwig, R., Matthes, U. (1996) Efficacy and safety 
profile of fumaric acid esters in oral long-term therapy with severe 
treatment refractory psoriasis vulgaris. A study of 83 patients. 
Hautarzt, 47, 190-196. 
[3]  Altmeyer, P.J., Matthes, U., Pawlak, F., Hoffmann, K., Frosch, P.J., 
Ruppert, P., Wassilew, S.W., Horn, T., Kreysel, H.W., Lutz, G. 
(1994) Antipsoriatic effect of fumaric acid derivatives. Results of a 
multicenter double-blind study in 100 patients. J. Am. Acad. Der-
matol., 30, 977-981. 
[4]  Asadullah, K., Schmid, H., Friedrich, M., Randow, F., Volk, H.D., 
Sterry, W., Docke, W.D. (1997) Influence of monomethylfumarate 
on monocytic cytokine formation--explanation for adverse and 
therapeutic effects in psoriasis? Arch. Dermatol. Res., 289, 623-
630. 
[5]  Bacharach-Buhles, M., Pawlak, F.M., Matthes, U., Joshi, R.K., 
Altmeyer, P. (1994) Fumaric acid esters (FAEs) suppress CD 15- 
and ODP 4-positive cells in psoriasis. Acta Derm. Venereol. Suppl. 
(Stockh), 186, 79-82. 
[6]  de Jong, R., Bezemer, A.C., Zomerdijk, T.P., Pouw-Kraan, T., 
Ottenhoff, T.H., Nibbering, P.H. (1996) Selective stimulation of T 
helper 2 cytokine responses by the anti-psoriasis agent monometh-
ylfumarate. Eur. J. Immunol., 26, 2067-2074. 
[7]  Hoefnagel, J.J., Thio, H.B., Willemze, R., Bouwes Bavinck, J.N. 
(2003) Long-term safety aspects of systemic therapy with fumaric 
acid esters in severe psoriasis. Br. J. Dermatol., 149, 363-369. 
[8]  Kappos, L., Miller, D., MacManus, D., Gold, R., Havrdova, E., 
Limmroth, V., Polman, C., Schmierer, K., Yousry, T., Yang, M., 
Erakosy, M., Meluzinova, E., Rektor, I., O´Neill, G. (2008) Oral 
fumarate (BG00012) for relapsing-remitting multiple sclerosis: re-
sults of a phase 2b study. Lancet, 372, 1463-1472. 
[9]  Kolbach, D.N., Nieboer, C. (1992) Fumaric acid therapy in psoria-
sis: results and side effects of 2 years of treatment. J. Am. Acad. 
Dermatol., 27, 769-771. 
[10]  Litjens, N.H., Burggraaf, J., van Strijen, E., van Gulpen, C., Mattie, 
H., Schoemaker, R.C., van Dissel, J.T., Thio, H.B., Nibbering, P.H. 
(2004) Pharmacokinetics of oral fumarates in healthy subjects. Br. 
J. Clin. Pharmacol., 58, 429-432. 
[11]  Litjens, N.H., Rademaker, M., Ravensbergen, B., Rea, D., van der 
Plas, M.J., Thio, B., Walding, A., van Dissel, J.T., Nibbering, P.H. 
(2004) Monomethylfumarate affects polarization of monocyte-
derived dendritic cells resulting in down-regulated Th1 lymphocyte 
responses. Eur. J. Immunol., 34, 565-575. 64    Current Neuropharmacology, 2009, Vol. 7, No. 1 Moharregh-Khiabani et al. 
[12]  Lukashev, M., Zeng, W., Ryan, S., Dawson, K., O´Neill, G.N., 
Goelz, S.E., Lee, D.H., Linker, R., Drukarch, B., Van Dam, A.M., 
Gold, R. (2008) Activation of Nrf2 and modulation of disease by 
BG00012 (Dimethyl Fumarate) suggest a dual cytoprotective and 
anti-inflammatory mechanism of action. Neurology, 70 (Suppl. 1), 
A27. 
[13]  Mrowietz, U., Altmeyer, P., Bieber, T., Rocken, M., Schopf, R.E., 
Sterry, W. (2007) Treatment of psoriasis with fumaric acid esters 
(Fumaderm). J. Dtsch. Dermatol. Ges., 5, 716-717. 
[14]  Mrowietz, U., Asadullah, K. (2005) Dimethylfumarate for psoria-
sis: more than a dietary curiosity. Trends Mol. Med., 11, 43-48. 
[15]  Mrowietz, U., Christophers, E., Altmeyer, P. (1998) Treatment of 
psoriasis with fumaric acid esters: results of a prospective multi-
centre study. German Multicentre Study. Br. J. Dermatol., 138,
456-460. 
[16]  Mrowietz, U., Christophers, E., Altmeyer, P. (1999) Treatment of 
severe psoriasis with fumaric acid esters: scientific background and 
guidelines for therapeutic use. The German Fumaric Acid Ester 
Consensus Conference. Br. J. Dermatol., 141, 424-429. 
[17]  Nast, A., Kopp, I., Augustin, M., Banditt, K.B., Boehncke, W.H., 
Follmann, M., Friedrich, M., Huber, M., Kahl, C., Klaus, J., Koza, 
J., Kreiselmaier, I., Mohr, J., Mrowietz, U., Ockenfels, H.M., 
Orzechowski, H.D., Prinz, J., Reich, K., Rosenbach, T., Rosumeck, 
S., Schlaeger, M., Schmid-Ott, G., Sebastian, M., Streit, V., We-
berschock, T., Rzany, B. (2007) German evidence-based guidelines 
for the treatment of Psoriasis vulgaris (short version). Arch. Der-
matol. Res., 299, 111-138. 
[18]  Nibbering, P.H., Thio, B., Zomerdijk, T.P., Bezemer, A.C., Bei-
jersbergen, R.L., van Furth, R. (1993) Effects of monomethylfu-
marate on human granulocytes. J. Invest. Dermatol., 101, 37-42. 
[19]  Ockenfels, H.M., Schultewolter, T., Ockenfels, G., Funk, R., Goos, 
M. (1998) The antipsoriatic agent dimethylfumarate immunomodu-
lates T-cell cytokine secretion and inhibits cytokines of the psori-
atic cytokine network. Br. J. Dermatol., 139, 390-395. 
[20]  Roll, A., Reich, K., Boer, A. (2007) Use of fumaric acid esters in 
psoriasis. Indian J. Dermatol. Venereol. Leprol., 73, 133-137. 
[21]  Schilling, S., Goelz, S., Linker, R., Luehder, F., Gold, R. (2006) 
Fumaric acid esters are effective in chronic experimental autoim-
mune encephalomyelitis and suppress macrophage infiltration. 
Clin. Exp. Immunol., 145, 101-107. 
[22]  Schimrigk, S., Brune, N., Hellwig, K., Lukas, C., Bellenberg, B., 
Rieks, M., Hoffmann, V., Pohlau, D., Przuntek, H. (2006) Oral fu-
maric acid esters for the treatment of active multiple sclerosis: an 
open-label, baseline-controlled pilot study. Eur. J. Neurol., 13,
604-610. 
[23]  Schweckendiek, W. (1959) Treatment of psoriasis vulgaris. Med. 
Monatsschr., 13, 103-104. 
[24]  Sebok, B., Bonnekoh, B., Vetter, R., Schneider, I., Gollnick, H., 
Mahrle, G. (1998) The antipsoriatic dimethyl-fumarate suppresses 
interferon-gamma -induced ICAM-1 and HLA-DR expression on 
hyperproliferative keratinocytes. Quantification by a culture plate-
directed APAAP-ELISA technique. Eur. J. Dermatol., 8, 29-32. 
[25]  Stoof, T.J., Flier, J., Sampat, S., Nieboer, C., Tensen, C.P., 
Boorsma, D.M. (2001) The antipsoriatic drug dimethylfumarate 
strongly suppresses chemokine production in human keratinocytes 
and peripheral blood mononuclear cells. Br. J. Dermatol., 144,
1114-1120. 
[26]  Treumer, F., Zhu, K., Glaser, R., Mrowietz, U. (2003) Dimethyl-
fumarate is a potent inducer of apoptosis in human T cells. J. In-
vest. Dermatol., 121, 1383-1388. 
[27]  Vandermeeren, M., Janssens, S., Borgers, M., Geysen, J. (1997) 
Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, 
VCAM-1, and ICAM-1 expression in human endothelial cells. Bio-
chem. Biophys. Res. Commun., 234, 19-23. 
[28]  Wakkee, M., Thio, H.B. (2007) Drug evaluation: BG-12, an immu-
nomodulatory dimethylfumarate. Curr. Opin. Investig. Drugs, 8,
955-962. 
[29]  Werdenberg, D., Joshi, R., Wolffram, S., Merkle, H.P., Langguth, 
P. (2003) Presystemic metabolism and intestinal absorption of an-
tipsoriatic fumaric acid esters. Biopharm. Drug Dispos., 24, 259-
273. 
[30]  Wierinckx, A., Breve, J., Mercier, D., Schultzberg, M., Drukarch, 
B., Van Dam, A.M. (2005) Detoxication enzyme inducers modify 
cytokine production in rat mixed glial cells. J. Neuroimmunol., 166,
132-143. 
[31]  Zhu, K., Mrowietz, U. (2001) Inhibition of dendritic cell differen-
tiation by fumaric acid esters. J. Invest. Dermatol., 116, 203-208. 
[32]  Zhu, K., Mrowietz, U. (2005) Enhancement of antibacterial super-
oxide-anion generation in human monocytes by fumaric acid esters. 
Arch. Dermatol. Res., 297, 170-176. 
Received: September 09, 2008  Revised: September 26, 2008  Accepted: September 30, 2008 